DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Antineoplastic and Immunomodulating Agents; Sensory Organ are 25

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0791	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (82.105 %)	Approved	27476412
DrugRepV_1539	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	MEX_I_7	NA	Flow cytometry	No significant effect (50 %)	Approved	27476412
DrugRepV_1542	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	MEX_I_7	NA	Flow cytometry	Increase (>200 %)	Approved	27476412
DrugRepV_1547	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	DAK_41525	NA	Flow cytometry	Increase (140 %)	Approved	27476412
DrugRepV_1559	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	No significant effect	Approved	27476412
DrugRepV_2291	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.58224242 %)	Approved	27742486
DrugRepV_2644	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.0495258 %)	Approved, Investigational	27742486
DrugRepV_3361	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immunosuppressant [treatment of transplant (kidney, liver, and heart) rejection], rheumatoid arthritis, severe psoriasis.	Middle East respiratory syndrome coronavirus	EMC/2012	NA	Cell proliferation assay	Decrease (100 %)	Approved	23620378
DrugRepV_3362	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immunosuppressant [treatment of transplant (kidney, liver, and heart) rejection], rheumatoid arthritis, severe psoriasis.	Middle East respiratory syndrome coronavirus	EMC/2012	NA	Cell proliferation assay	Decrease (80 %)	Approved	23620378
DrugRepV_4737	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (60 %)	Approved, Investigational	25487801
DrugRepV_5146	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	Approved, Investigational	29652799
DrugRepV_5157	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (2log pfu/ml)	Approved, Investigational	29652799
DrugRepV_5165	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	MP12-Luc	NA	Luciferase assay	Decrease (50 %)	Approved, Investigational	28442428
DrugRepV_5166	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	MP12	NA	Western blot	Decrease	Approved, Investigational	28442428
DrugRepV_5167	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (2 log pfu/ml)	Approved, Investigational	28442428
DrugRepV_5168	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	ZH501	NA	Plaque assay	Decrease (1 log pfu/ml)	Approved, Investigational	28442428
DrugRepV_5169	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	MP12	NA	Real-time PCR	Decrease (2 log Genomic Copies)	Approved, Investigational	28442428
DrugRepV_5170	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	ZH501	NA	Survival assay	Increase	Approved, Investigational	28442428
DrugRepV_5571	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved, Investigational	32353859
DrugRepV_5815	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Dengue virus	NA		Immunoflourescence assay	Decrease (55.12 %)	Approved, Investigational	22155902
DrugRepV_6328	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (55.12 %)	Approved, Investigational	22155902
DrugRepV_7048	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (30 %)	Approved	28814523
DrugRepV_7052	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (45 %)	Approved	28814523
DrugRepV_7641	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020	NA	Immunofluorescence	Decrease (50 %)	Approved	32438446
DrugRepV_7642	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020	NA	Immunofluorescence	Decrease (90 %)	Approved	32438446